Effects of Gluten Free Diet in Ulcerative Colitis

Ulcerative Colitis Clinical Trial

Official title:

Effects of Dietary Gluten on Gastrointestinal Symptoms in Ulcerative Colitis: a Randomised Crossover Trial.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06249763
• Other study ID #: Gluten-UC
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 2024
• Est. completion date: May 2025

Study information

• Verified date: February 2024
• Source: University of Southern Denmark
• Contact: Vibeke Andersen, Prof
• Phone: 004521157790
• Email: vandersen[@]health.sdu.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal is to evaluate gastrointestinal symptoms and fatigue levels during a period of eating gluten free compared to a period of high gluten consumption in individuals with confirmed Ulcerative Colitis, and to identify clinical characteristics in the blood and microbiome of those improving from a gluten free diet. The main questions, the project aims to answer are: - What is the effect of eating gluten free on patient-reported gastrointestinal symptoms in patients with Ulcerative Colitis? - What is the effect of eating gluten free on patient-reported fatigue levels in patients with Ulcerative Colitis? - What are clinical differences between those improving and not improving on fatigue levels and gastrointestinal symptoms? During two study periods of one week each, participants will be eating gluten free supplemented with daily granola bars without and with high gluten content, respectively. During each active week, participants are asked to: - Eat gluten free and two daily granola bars delivered by the research team - Collect blood, stool and urine samples - Answer questionnaires about their symptoms, disease course, habitual lifestyle, and compliance to the protocol

Description:

Introduction: To meet the growing demand for lifestyle recommendations among patients Ulcerative Colitis (UC) for managing their symptoms and wellbeing, this study aims to evaluate the use of the gluten free diet in the management of UC. Exposure to gluten can activate pro-inflammatory signals in the epithelium that induce mucosal damage, and the protein has previously been associated with disease activity in inflammatory bowel disease, including UC. A suggested pathway for the interaction between disease course and gluten intake is via mucosal damage followed by a flow of pathogens across the intestinal barrier. To our knowledge, the effect of gluten on UC disease course is not fully understood, and clinical characteristics of patients benefitting from the gluten free diet has not yet been studied. To the patients, fatigue and pain from the gastrointestinal tract are the most burdensome symptoms of UC affecting life quality and restricting everyday activities for the patients. Hence, this study aims to evaluate the effects of dietary gluten in the management of gastrointestinal symptoms and fatigue in UC, and to identify clinical characteristics of patients with UC benefitting from eating gluten free. Design: In this crossover randomized trial, the outcomes will be assessed after a one-week period of a high-gluten diet and a one-week period of a gluten free diet. Participants and study personnel will be blinded to the dietary intake by granola bars supplementing a complete gluten free diet. The intake of dietary fibres and fructans will be controlled and monitored and controlled for. Setting: Participants will be recruited from the outpatient clinics for Gastrointestinal Diseases at Hospital Sønderjylland (Hospital of Southern Jutland) in the city of Aabenraa from from January to May 2024. Data collection will be completed in 2024. Clinical data consist of personal data, patient-reported data on disease activity, gastrointestinal symptoms, fatigue level, health related quality of life and dietary intake, biomarkers in blood, urine and faeces, and protocol compliance measures. Information registered by clinicians and technicians will be transferred from paper format to electronic format using either double entry of data or automated forms processing. Biologic material consist of blood, faeces and urine samples. All data are treated confidentially and stored according to the Danish Data Protection Regulation and Data Protection Law. Sample size considerations: Sample size estimation was based on a 1.00 difference in the gastrointestinal symptoms score with a standard deviation (SD) of 1.80 which at a 5% significance level (two-sided) and with 80% statistical power would require a sample size of 28 completing participants. Consequently it was decided to aim for a total sample size of 30 participants, corresponding to a statistical power of 84%. Project organization: The project is part of a PhD (doctor of philosophy) study. Collaborators are specialists from the gastrointestinal, biochemical and microbiology departments involved in the project and professors in biostatistics and food sciences. The study is approved by the local Ethics Committee (S-20210174) and the local Data Agency (22/39335). The study findings will be disseminated in peer-reviewed journals, via patient associations, and presented at national and international conferences.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: May 2025
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis: Ulcerative Colitis (UC)
• Language: Can read and understand Danish
• Treatment: No intention to change dose of, begin, or switch medication and biologic treatment within one month after inclusion
• Treatment: Medical and/or biologic treatment type and dose stable for at least 8-16 weeks prior to inclusion depending on the type of treatment

Exclusion Criteria:

• Age: <18 years
• Severe disease activity defined by 6 or more bloody stools per day and/or night and one of the following: fever, pulse = 90, C-reactive protein (CRP) = 30mg/L by the time of inclusion
• Treatment: Have received antibiotic treatment within 4 weeks prior to inclusion
• Treatment: Previous operation for UC
• Concomitant diagnoses: Coeliac Disease (positive Immunoglobolin A against transglutaminase, TGA-IgA) or any cancer diagnosis
• Other: Taking probiotics, are pregnant or breastfeeding, or have nut or wheat allergy

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Inflammatory Bowel Diseases
• Ulcer
• Ulcerative Colitis

Intervention

Dietary Supplement:
• High gluten diet
Trial period A: gluten free diet added daily granola bars with 10 g gluten/day (intervention).
• Gluten free diet
Trial period B: gluten free diet added daily granola bars with <1 g gluten/day (placebo).

Locations

Country	Name	City	State
Denmark	Hospital of Southern Jutland	Aabenraa

Sponsors (5)

Lead Sponsor	Collaborator
University of Southern Denmark	Colitis-Crohn Foreningen, Hospital of Southern Jutland, Odense University Hospital, University Hospital Bispebjerg and Frederiksberg

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Microbiome data	Microbiome sequencing of urine and faecal samples	1 week
Other	Potential biomarkers	Potential biomarkers in biologic material	1 week
Primary	Gastrointestinal symptoms	The Gastrointestinal Symptom Rating Scale (GSRS)	1 week
Secondary	Fatigue	Section I of the Inflammatory Bowel Disease Fatigue patient self-assessment scale (IBD-F) modified to assess the previous week	1 week
Secondary	Disease activity	Simple Clinical Colitis Activity Index (SCCAI)	1 week
Secondary	Symptom burden	Symptom burden measured on the Short Health Scale (SHS)	1 week
Secondary	Functional status	Functional status measured on the Short Health Scale (SHS)	1 week
Secondary	Disease-related health burden	Disease-related health burden measured on the Short Health Scale (SHS)	1 week
Secondary	General well-being	General well-being measured on the Short Health Scale (SHS)	1 week
Secondary	Joint pain	100 mm visual analogue scale (VAS)	1 week
Secondary	Stool consistency	the Bristol Stool Form Scale (BSFS)	1 week
Secondary	Faecal Calprotectin (f-Cal)	Intestinal inflammatory biomarker	1 week
Secondary	C-reactive protein (CRP)	Acute phase reactant	1 week
Secondary	Serum-Zonulin	Exploratory measure of intestinal permeability: Zonulin levels in blood and faeces	1 week
Secondary	Faecal-Zonulin	Exploratory measure of intestinal permeability: Zonulin levels in blood and faeces	1 week
Secondary	Dietary compliance: diet intake	Participant reported compliance to the diet (y/n), e.g. dietary gluten and fructan intake and the number of remaining granola bars by the end of a trial period	1 week
Secondary	Urine-Gluten Immunogenic Peptides (GIP)	Supplementing dietary compliance measure: Presence of GIP in urine	1 week